Last Updated: 16 Sep 2024
Executive Summary
Hoth Therapeutics Inc. (HOTH) is a biopharmaceutical company focused on developing therapies for dermatological disorders. The company has a market capitalization of $7.59 million and is currently trading at $1.1 per share. Analysts have a Buy rating on the stock, with a target price of $4.
Company Overview
Hoth Therapeutics was founded in 2017 and is headquartered in New York, New York. The company's lead product candidate is HT-001, a topical cream for the treatment of atopic dermatitis. HT-001 is currently in Phase 2 clinical trials.
Fundamental Analysis
Hoth Therapeutics is a pre-revenue company, so it does not have any financial data to analyze. However, the company has a strong pipeline of product candidates and a team of experienced executives.
Technical Analysis
HOTH is currently trading below its 50-day and 200-day moving averages. The stock is also in a downtrend, as it has been making lower highs and lower lows since early 2023.
Short Term Outlook
The short-term outlook for HOTH is negative. The stock is trading below its moving averages and is in a downtrend. However, the stock could see a short-term bounce if it can break above its 50-day moving average.
Long Term Outlook
The long-term outlook for HOTH is positive. The company has a strong pipeline of product candidates and a team of experienced executives. If HT-001 is successful in clinical trials, HOTH could become a valuable company.
Analyst Recommendations
Analysts have a Buy rating on HOTH, with a target price of $4. The analysts believe that HOTH is a undervalued company with a strong pipeline of product candidates.
